Israel 1986b.

Methods	Allocation concealment: not stated. Authors state "randomly allocated". 2 women with side‐effects on hydralazine crossed over to pindolol + hydralazine, and reported in this group. Data only included if available as intention‐to‐treat. Two arms
Participants	44 women at < 37 weeks with BP >/= 150/90 mmHg x 2 at least 24 hrs apart. Excluded: insulin‐dependent diabetes, obstructive lung disease, contraindication to pindolol or hydralazine.
Interventions	Exp: oral hydralazine 50 mg/day to 100 mg/day + oral pindolol 10 mg/day to 25 mg/day (in 2 daily doses). (21 women) Control: oral hydralazine 50 mg/day to 100 mg/day (in 2 daily doses). (23 women)
Outcomes	Women: severe HT, proteinuria (> 1 g in 24 hr), side‐effects, changed drug due to side‐effects, caesarean section. Babies: preterm delivery, SGA (< 250 on Usher's curve), hypoglycaemia, hypothermia, low Apgar score.
Notes	No mention of which Korotkoff sound used. Funding: no information about funding source. Declaration of interests not described.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described: "...randomly allocated...". No further details.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label trial.
Blinding of outcome assessment (detection bias) All outcomes	High risk	No.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No.
Selective reporting (reporting bias)	Unclear risk	Assessment from published study report.
Other bias	Unclear risk	Groups appear comparable at baseline. 2 women with side‐effects on hydralazine crossed over to pindolol + hydralazine, and reported in this group. Data only included if available as intention‐to‐treat. No information about funding source. Declaration of interests not described.